6 results on '"Treatment drug"'
Search Results
2. Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
- Author
-
Inoue, Hideka, Morino, Katsutaro, Ugi, Satoshi, Tanaka‐Mizuno, Sachiko, Fuse, Keiko, Miyazawa, Itsuko, Kondo, Keiko, Sato, Daisuke, Ohashi, Natsuko, Ida, Shogo, Sekine, Osamu, Yoshimura, Masahiro, Murata, Kiyoshi, Miura, Katsuyuki, Arima, Hisatomi, and Maegawa, Hiroshi more...
- Subjects
- *
SODIUM-glucose cotransporters , *MUSCLE mass , *TYPE 2 diabetes , *CLINICAL trials , *PEOPLE with diabetes , *BODY mass index , *IPRAGLIFLOZIN - Abstract
Aims/Introduction: Sodium–glucose cotransporter 2 inhibitors reduce bodyweight (BW) by creating a negative energy balance. Previous reports have suggested that this BW reduction is mainly loss of body fat and that ~20% of the reduction is lean mass. However, the effects of sodium–glucose cotransporter 2 inhibitors on BW and body composition remain unclear. We examined these effects in Japanese patients with type 2 diabetes mellitus treated with insulin. Materials and Methods: In this open‐label, randomized controlled trial, 49 overweight patients (body mass index ≥23 kg/m2) with inadequate glycemic control (hemoglobin A1c >7.0%) receiving insulin treatment were randomly assigned to receive add‐on ipragliflozin or no additional treatment (control group). Patients were followed for 24 weeks. The goal for all patients was to achieve glycated hemoglobin <7.0% without hypoglycemia. The primary end‐point was a change in BW from baseline to week 24. Body composition was assessed with dual‐energy X‐ray absorptiometry and bioelectrical impedance analysis. Results: BW change was significantly larger in the ipragliflozin group than in the control group (−2.78 vs −0.22 kg, P < 0.0001). Total fat mass was reduced evenly in the arms, lower limbs and trunk in the ipragliflozin group. Total muscle mass and bone mineral content were maintained, but muscle mass in the arms might have been affected by ipragliflozin treatment. Conclusions: Ipragliflozin treatment for 24 weeks resulted in reduced BW, mainly from fat mass loss. Muscle mass and bone mineral content were maintained. Further study is necessary to elucidate the long‐term effects of ipragliflozin. [ABSTRACT FROM AUTHOR] more...
- Published
- 2019
- Full Text
- View/download PDF
Catalog
3. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome.
- Author
-
Yokota, Takashi, Kinugawa, Shintaro, Hirabayashi, Kagami, Suga, Tadashi, Takada, Shingo, Omokawa, Masashi, Kadoguchi, Tomoyasu, Takahashi, Masashige, Fukushima, Arata, Matsushima, Shouji, Yamato, Mayumi, Okita, Koichi, and Tsutsui, Hiroyuki more...
- Subjects
- *
SKELETAL muscle , *PIOGLITAZONE , *AEROBIC capacity , *METABOLIC syndrome , *ENERGY metabolism , *DISEASES - Abstract
Aims/Introduction Low aerobic capacity is a strong and independent predictor of all-cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole-body aerobic capacity and skeletal muscle energy metabolism in MetS patients. Materials and Methods A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole-body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high-energy phosphates in the calf muscle during plantar-flexion exercise were measured using 1proton- and 31phosphorus magnetic resonance spectroscopy, respectively. Results Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post- treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post-treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high-energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. Conclusions Pioglitazone significantly improved the MetS patients' whole-body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole-body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle. [ABSTRACT FROM AUTHOR] more...
- Published
- 2017
- Full Text
- View/download PDF
4. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
- Author
-
Mayumi Yamato, Takashi Yokota, Koichi Okita, Hiroyuki Tsutsui, Masashi Omokawa, Masashige Takahashi, Shouji Matsushima, Shintaro Kinugawa, Shingo Takada, Tomoyasu Kadoguchi, Arata Fukushima, Tadashi Suga, and Kagami Hirabayashi more...
- Subjects
Adult ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Phosphates ,Phosphocreatine ,03 medical and health sciences ,chemistry.chemical_compound ,Clinical ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Hypoglycemic Agents ,Muscle, Skeletal ,Aerobic capacity ,Pioglitazone ,Fatty acid metabolism ,business.industry ,Skeletal muscle ,VO2 max ,Articles ,General Medicine ,Middle Aged ,Lipid Metabolism ,medicine.disease ,Metabolic syndrome ,Oxidative Stress ,Clinical Science and Care ,medicine.anatomical_structure ,Endocrinology ,chemistry ,Treatment drug ,Original Article ,Thiazolidinediones ,Energy Metabolism ,business ,Anaerobic exercise ,medicine.drug - Abstract
Aims/Introduction Low aerobic capacity is a strong and independent predictor of all-cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole-body aerobic capacity and skeletal muscle energy metabolism in MetS patients. Materials and Methods A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole-body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high-energy phosphates in the calf muscle during plantar-flexion exercise were measured using 1proton- and 31phosphorus magnetic resonance spectroscopy, respectively. Results Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post- treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post-treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high-energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. Conclusions Pioglitazone significantly improved the MetS patients’ whole-body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole-body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle. more...
- Published
- 2017
5. Venous Pain of Lower Limbs in Daily Phlebology Clinical and Therapeutic Study
- Author
-
Tartour, J., Lenica, D., Gallo, R., Negus, David, editor, Jantet, Georges, editor, and Coleridge-Smith, Philip D., editor
- Published
- 1995
- Full Text
- View/download PDF
6. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
- Author
-
1000090374321, Yokota, Takashi, 1000060399871, Kinugawa, Shintaro, Hirabayashi, Kagami, 1000030708673, Suga, Tadashi, 1000060722329, Takada, Shingo, Omokawa, Masashi, Kadoguchi, Tomoyasu, Takahashi, Masashige, 1000040706553, Fukushima, Arata, Matsushima, Shouji, 1000030380695, Yamato, Mayumi, 1000080382539, Okita, Koichi, 1000070264017, Tsutsui, Hiroyuki, 1000090374321, Yokota, Takashi, 1000060399871, Kinugawa, Shintaro, Hirabayashi, Kagami, 1000030708673, Suga, Tadashi, 1000060722329, Takada, Shingo, Omokawa, Masashi, Kadoguchi, Tomoyasu, Takahashi, Masashige, 1000040706553, Fukushima, Arata, Matsushima, Shouji, 1000030380695, Yamato, Mayumi, 1000080382539, Okita, Koichi, 1000070264017, and Tsutsui, Hiroyuki more...
- Abstract
Aims/Introduction: Low aerobic capacity is a strong and independent predictor of all-cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole-body aerobic capacity and skeletal muscle energy metabolism in MetS patients. Materials and Methods: A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole-body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high-energy phosphates in the calf muscle during plantar-flexion exercise were measured using 1proton- and 31phosphorus magnetic resonance spectroscopy, respectively. Results: Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post- treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post-treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high-energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. Conclusions: Pioglitazone significantly improved the MetS patients' whole-body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole-body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle. more...
- Published
- 2017
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.